bluuebunny/crossref_metadata_2025 huggingface dataset:
Ribosomal Protein Cluster Organization in Asgard Archaea
Authors: Tirumalai Madhan R. , Sivaraman Raghavan V. , Kutty Layla A. , Song Eric L. , Fox George E.
Published: September 2023

It has been proposed that the superphylum of Asgard Archaea may represent a historical link between the Archaea and Eukarya. Following the discovery of the Archaea, it was soon appreciated that archaeal ribosomes were more similar to those of Eukarya rather than Bacteria. Coupled with other eukaryotic-like features, it has been suggested that the Asgard Archaea may be directly linked to eukaryotes. However, the genomes of Bacteria and non-Asgard Archaea generally organize ribosome-related genes into clusters that likely function as operons. In contrast, eukaryotes typically do not employ an operon strategy. To gain further insight into conservation of the r-protein genes, the genome order of conserved ribosomal protein (r-protein) coding genes was identified in 17 Asgard genomes (thirteen complete genomes and four genomes with less than 20 contigs) and compared with those found previously in non-Asgard archaeal and bacterial genomes. A universal core of two clusters of 14 and 4 cooccurring r-proteins, respectively, was identified in both the Asgard and non-Asgard Archaea. The equivalent genes in the E. coli version of the cluster are found in the S10 and spc operons. The large cluster of 14 r-protein genes (uS19-uL22-uS3-uL29-uS17 from the S10 operon and uL14-uL24-uL5-uS14-uS8-uL6-uL18-uS5-uL30-uL15 from the spc operon) occurs as a complete set in the genomes of thirteen Asgard genomes (five Lokiarchaeotes, three Heimdallarchaeotes, one Odinarchaeote, and four Thorarchaeotes). Four less conserved clusters with partial bacterial equivalents were found in the Asgard. These were the L30e (str operon in Bacteria) cluster, the L18e (alpha operon in Bacteria) cluster, the S24e-S27ae-rpoE1 cluster, and the L31e, L12..L1 cluster. Finally, a new cluster referred to as L7ae was identified. In many cases, r-protein gene clusters/operons are less conserved in their organization in the Asgard group than in other Archaea. If this is generally true for nonribosomal gene clusters, the results may have implications for the history of genome organization. In particular, there may have been an early transition to or from the operon approach to genome organization. Other nonribosomal cellular features may support different relationships. For this reason, it may be important to consider ribosome features separately.
Influence of Layering Pattern, Fibre Architecture, and Alkalization on Physical, Mechanical, and Morphological Behaviour of Banana Fibre Epoxy Composites
Authors: Gebremaryam Gezahgn , Shahapurkar Kiran , Chenrayan Venkatesh , Althoey Fadi , Hadidi Haitham M. , Soudagar Manzoore Elahi M. , Tirth Vineet , Algahtani Ali , Al-Mughanam Tawfiq , Alghtani Abdulaziz H. , Murthy H. C. Ananda
Published: September 2023

In the current investigation, the mechanical properties of epoxy composites reinforced with banana pseudostem fibres, specifically focusing on tensile and impact behaviour, are investigated. The manufacturing process employed the meticulous hand-lay-up technique to fabricate six distinct samples. These samples included various combinations of short and woven banana fibres, treated and untreated, as well as a hybrid configuration involving layers of woven and short fibres. A fixed weight ratio of 60% fibres to 40% epoxy matrix was maintained for consistency. To ensure optimal material integrity, a careful application of resin and hardener in a 10 : 1 weight ratio was layered, with each addition of fibre followed by thorough rolling to eliminate any potential bubbles. The density and void fraction of the resulting composites were meticulously assessed to gauge the influence of this layering approach. Additionally, an X-ray diffraction (XRD) analysis was conducted to ascertain the impact of the chemical treatment on the cellulose content of the fibres. Our findings revealed that the tensile and impact properties were notably superior in the woven fibre composites. In particular, the chemically treated woven banana fibre epoxy composite displayed impressive values of 64.95 MPa for tensile strength and 24.37 KJ/m2 for impact strength. To gain deeper insights into the structure-property relationship, test specimens were analyzed using scanning electron micrographs. Lastly, comparative analysis by mapping the tensile properties from our present work with those from existing studies was carried out.
Alkaline-Stable, In Situ Menshutkin Coat and Curable Ammonium Network: Ion-Solvating Membranes for Anion Exchange Membrane Water Electrolyzers
Authors: Jung Jiyoon , Park Young Sang , Choi Gwan Hyun , Park Hyun Jin , Ahn Cheol-Hee , Hwang Seung Sang , Lee Albert S.
Published: September 2023

Anion exchange membranes fabricated through a one-step Menshutkin reaction with down-selected multifunctional alkyl halides and multifunctional tertiary amines within an ion-solvating matrix, poly(ethylene-co-vinyl alcohol), yielded alkaline-stable ammonium network polymers. Due to the vast simplicity in fabrication due to the quaternization/Menshutkin reaction between tertiary amine and alkyl bromides, which does not evolve any by-products that require purification, alkaline-stable membranes were fabricated in one step through facile mixing and curing of alkaline-stable ammonium network forming monomers. Prepared membranes showed controllable ion exchange capacity (IEC), conductivity, and mechanical strength by controlling of poly(ethylene-co-vinyl alcohol) amount which is an ion-solvating polymer. The selection of ammonium network chemical structure allowed for flawless retention of IEC and conductivity under conditions of 70°C, 1M KOH of over 300 h. Anion exchange membrane electrolysis membrane electrode assembly tests with optimized membranes showed a greater performance (1.78 A/cm2 at 2.0 V) and more enhanced water electrolyzer durability than that of commercial anion exchange membrane.
Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: October 2023

Supplementary Tables S2-13
Supplementary Table S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: October 2023

Table S1
Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: October 2023

Supplementary Fig. S6. Effect of hormone deprivation and NFKB pathway activation HR+ breast cancer cells.
Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: October 2023

Supplementary Fig. S2. Comprehensive analysis of protein expression changes before and after endocrine treatment
Figure 4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: October 2023

Estrogen deprivation upregulates IFNγ response through NF-κB signaling. A, RNA-seq analysis of MCF-7 cells grown in HD conditions or in the presence of E2 for three days. The volcano plot shows genes differently expressed between HD- and E2-treated conditions (log2FC>1, Padj < 0.01). Number on the top shows the total number of genes differentially expressed for each condition. B, GSEA of upregulated pathways in E2-stimulated cells. C, GSEA of upregulated pathways in the HD condition. D, Three-cluster K-means plot of genes without and with IFNγ stimulation at different time points in cells grown in HD or E2 conditions with and without E2 for three days. E–G, Hallmark pathway analysis of “E2-induced” genes (E), “IFNγ early” (F), and “IFNγ late” (FDR < 0.05; G). H, Supervised heat map of the expression of IFNγ and antigen presentation-related genes in E2-treated and HD condition without and with IFNγ treatment. I–J, ATAC-seq that was performed in MCF7 cells grown in the presence or absence of E2 for 48 hours and followed by ± IFNγ 10 ng/mL stimulation for 24 hours. I, Tornado plots of chromatin accessibility sites based on ATAC-seq showing accessible sites significantly different between E2 and HD conditions showing IFNγ-treated or no IFNγ-treated conditions. J, Tornado plots showing the chromatin sites accessibly induced by IFNγ stimulation in E2 versus HD conditions. K, Motifs enriched in the chromatin accessible sites in J.
Supplementary Data from Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity
Authors: Yang Moon Hee , Tran Timothy H. , Hunt Bethany , Agnor Rebecca , Johnson Christian W. , Shui Bing , Waybright Timothy J. , Nowak Jonathan A. , Stephen Andrew G. , Simanshu Dhirendra K. , Haigis Kevin M.
Published: October 2023

Supplementary Figures 1-5, Tables 1-3
Figure 1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: October 2023

Digital spatial analysis. A, Schema of the endocrine therapy for PELOPS (NCT02764541). Numbers (N) represent the number of tissue samples included in the digital spatial profiling. B, Representative images of immunofluorescence staining for the regions of interest. CD45, cyan; E-cadherin, red; pan-cytokeratin, green. The magnified panels represent two ROIs; immune (#6) and invasive epithelial cells (#2). C–E, Volcano plot of log2-fold changes and adjusted P values of tests for differential protein expression comparing pre and post 24 weeks of endocrine treatment (2 weeks vs. surgical) within invasive epithelial cellular regions (C) and corresponding individual average patient trajectories for β2-microglobulin (D) and PR (E). F–H, Volcano plot of log2-fold changes and adjusted P values of tests for differential protein expression comparing pre and post 24 weeks of endocrine treatment (2 weeks versus surgical) within immune regions (F) and corresponding individual mean patient trajectories for β2-microglobulin (G) and CD4 (H). Horizontal dotted line denotes a 5% FDR threshold.
Supplementary Table S4 from Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma
Authors: Yanagawa Jane , Tran Linh M. , Salehi-Rad Ramin , Lim Raymond J. , Dumitras Camelia , Fung Eileen , Wallace William D. , Prosper Ashley E. , Fishbein Gregory , Shea Conor , Hong Rui , Kahangi Bitta , Deng John J. , Gower Adam C. , Liu Bin , Campbell Joshua D. , Mazzilli Sarah A. , Beane Jennifer E. , Kadara Humam , Lenburg Marc E. , Spira Avrum E. , Aberle Denise R. , Krysan Kostyantyn , Dubinett Steven M.
Published: October 2023

DEGs between subsolid nodule and nLung C20 NKT cells
Supplementary Figures from Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma
Authors: Yanagawa Jane , Tran Linh M. , Salehi-Rad Ramin , Lim Raymond J. , Dumitras Camelia , Fung Eileen , Wallace William D. , Prosper Ashley E. , Fishbein Gregory , Shea Conor , Hong Rui , Kahangi Bitta , Deng John J. , Gower Adam C. , Liu Bin , Campbell Joshua D. , Mazzilli Sarah A. , Beane Jennifer E. , Kadara Humam , Lenburg Marc E. , Spira Avrum E. , Aberle Denise R. , Krysan Kostyantyn , Dubinett Steven M.
Published: October 2023

Figure S1 - S8, Table S1-S2
Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Authors: Navarro-Yepes Juliana , Kettner Nicole M. , Rao Xiayu , Bishop Cassandra Santaella , Bui Tuyen N. , Wingate Hannah F. , Singareeka Raghavendra Akshara , Wang Yan , Wang Jing , Sahin Aysegul A. , Meric-Bernstam Funda , Hunt Kelly K. , Damodaran Senthil , Tripathy Debu , Keyomarsi Khandan
Published: October 2023

This file contains all the supplementary materials and methods referred to in the text.
Table S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Yu Shiyi , Wang Ying , Gong Xue , Fan Zhehao , Wang Zheng , Liang Zhengyan , Wu Rui , Cao Binjie , Wang Ning , Bi Caili , Lv Dan , Sun Haibo
Published: October 2023

Table S7
Supplemental Figures and Figure Legends from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Authors: Navarro-Yepes Juliana , Kettner Nicole M. , Rao Xiayu , Bishop Cassandra Santaella , Bui Tuyen N. , Wingate Hannah F. , Singareeka Raghavendra Akshara , Wang Yan , Wang Jing , Sahin Aysegul A. , Meric-Bernstam Funda , Hunt Kelly K. , Damodaran Senthil , Tripathy Debu , Keyomarsi Khandan
Published: October 2023

The attached file contains 12 Supplemental Figures and Figure Legnds
Table S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Yu Shiyi , Wang Ying , Gong Xue , Fan Zhehao , Wang Zheng , Liang Zhengyan , Wu Rui , Cao Binjie , Wang Ning , Bi Caili , Lv Dan , Sun Haibo
Published: October 2023

Table S6
Table S5 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Yu Shiyi , Wang Ying , Gong Xue , Fan Zhehao , Wang Zheng , Liang Zhengyan , Wu Rui , Cao Binjie , Wang Ning , Bi Caili , Lv Dan , Sun Haibo
Published: October 2023

Table S5
Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Yu Shiyi , Wang Ying , Gong Xue , Fan Zhehao , Wang Zheng , Liang Zhengyan , Wu Rui , Cao Binjie , Wang Ning , Bi Caili , Lv Dan , Sun Haibo
Published: October 2023

Figure S8R
Figure S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Yu Shiyi , Wang Ying , Gong Xue , Fan Zhehao , Wang Zheng , Liang Zhengyan , Wu Rui , Cao Binjie , Wang Ning , Bi Caili , Lv Dan , Sun Haibo
Published: October 2023

Figure S6
Figure S2 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Authors: Yu Shiyi , Wang Ying , Gong Xue , Fan Zhehao , Wang Zheng , Liang Zhengyan , Wu Rui , Cao Binjie , Wang Ning , Bi Caili , Lv Dan , Sun Haibo
Published: October 2023

Figure S2
Supplementary Figure Legends from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Authors: Nambiar Dhanya K. , Viswanathan Vignesh , Cao Hongbin , Zhang Weiruo , Guan Li , Chamoli Manish , Holmes Brittany , Kong Christina , Hildebrand Rachel , Koong Amanda Jeanette , von Eyben Rie , Plevritis Sylvia , Li Lingyin , Giaccia Amato , Engleman Edgar , Le Quynh Thu
Published: October 2023

sh-RNA knockdown sequences used in the study
Supplementary Figure 3 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Authors: Nambiar Dhanya K. , Viswanathan Vignesh , Cao Hongbin , Zhang Weiruo , Guan Li , Chamoli Manish , Holmes Brittany , Kong Christina , Hildebrand Rachel , Koong Amanda Jeanette , von Eyben Rie , Plevritis Sylvia , Li Lingyin , Giaccia Amato , Engleman Edgar , Le Quynh Thu
Published: October 2023

A. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the liver and kidneys of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes in comparison with naïve mice. B. Gating strategy used to quantify Arginase (Arg1) and interleukin-10 (IL-10) expression on PMN-MDSCs isolated from the tumor or the lungs of naïve mice or mice with pre-metastatic niches (sub-gated on CD45+ live cells). C. Heat map showing differential gene expression from PMN-MDSCs isolated from tumor and lung tissues of MOC2 WT-Gal1 tumor-bearing mice compared with naïve neutrophils. D. STRING analysis showing two clusters of genes representing IL-17 and collagen synthesis pathways that are upregulated PMN-MDSCs isolated from pre-metastatic lung tissues. E. Reactome pathway enrichment analyses performed using RNA-SEQ data showing pathway represented by upregulated genes in PMN-MDSCs isolated from pre-metastatic lung tissues. F. Quantification of Trichrome staining intensity in mEERL WT- or KO-Gal1 tumor-bearing mice lungs, n=5/group. G. tSNE plot showing depletion of PMN-MDSCs in the blood following injection of anti-GR1 antibody in mice compared with isotype alone.
Supplementary Figure 1 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Authors: Nambiar Dhanya K. , Viswanathan Vignesh , Cao Hongbin , Zhang Weiruo , Guan Li , Chamoli Manish , Holmes Brittany , Kong Christina , Hildebrand Rachel , Koong Amanda Jeanette , von Eyben Rie , Plevritis Sylvia , Li Lingyin , Giaccia Amato , Engleman Edgar , Le Quynh Thu
Published: October 2023

A. Terminal Tumor volume of MOC2 WT/KO-Gal1 tumors in Rag2-/- IL2rg-/- mice. B. Gating strategy used for analyses of PMN-MDSCs and M-MDSCs in tumor and lung tissues. C. Unsupervised tSNE clustering of live cells in MOC2 WT/KO-Gal1 tumor showing the proportion of M-MDSC, PMN-MDSC, and CD8+ T cells. D. Visual representation of the spleens isolated from either naïve mice or mice bearing WT- or KO-Gal1 tumors. E. Comparison of MDSC enrichment scores between smaller T1-2 and larger T3-4 tumors in the HNSCC TCGA cohort. The student’s t-test was used to assess the significance of the difference between the two groups. F. Heat map showing gene expression clustering based on the MDSC enrichment score in the HNSCC TCGA cohort. Differentially expressed genes (DEGs) were defined by a false discovery rate smaller than 0.05 and fold change higher than 1.5. G. Representative images showing low and high staining Gal1 or LOX1 (OLR1, established marker of PMN-MDSCs) using immunohistochemistry (IHC). H. Table showing the distribution of tumors expressing high or low Gal1 and high or low LOX1 (PMN-MDSCs) in 81 patients with oral cavity tumors. Gal1 and LOX1 staining distribution was analyzed using a chi-square test and was not statistically significant.
Data from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
Authors: Ito Ichiaki , Yousef Abdelrahman M.G. , Chowdhury Saikat , Dickson Princess N. , Naini Zahra A. , White Michael G. , Fleten Karianne G. , Flatmark Kjersti , Fournier Keith F. , Fowlkes Natalie W. , Shen John Paul
Published: October 2023

Abstract
Appendiceal adenocarcinomas (AA) are a rare and heterogeneous mix of tumors for which few preclinical models exist. The rarity of AA has made performing prospective clinical trials difficult, which has partly contributed to AA remaining an orphan disease with no chemotherapeutic agents approved by the FDA for its treatment. AA has a unique biology in which it frequently forms diffuse peritoneal metastases but almost never spreads via a hematogenous route and rarely spreads to lymphatics. Given the localization of AA to the peritoneal space, intraperitoneal delivery of chemotherapy could be an effective treatment strategy. Here, we tested the efficacy of paclitaxel given by intraperitoneal administration using three orthotopic patient-derived xenograft (PDX) models of AA established in immunodeficient NSG mice. Weekly intraperitoneal paclitaxel treatment dramatically reduced AA tumor growth in all three PDX models. Comparing the safety and efficacy of intravenous with intraperitoneal administration, intraperitoneal delivery of paclitaxel was more effective, with reduced systemic side effects in mice. Given the established safety record of intraperitoneal paclitaxel in gastric and ovarian cancers, and lack of effective chemotherapeutics for AA, these data showing the activity of intraperitoneal paclitaxel in orthotopic PDX models of mucinous AA support the evaluation of intraperitoneal paclitaxel in a prospective clinical trial.
Significance:
The activity and safety of intraperitoneal paclitaxel in orthotopic PDX models of mucinous appendiceal adenocarcinoma supports the evaluation of intraperitoneal paclitaxel in a prospective clinical trial of this rare tumor type.
Data from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Authors: Navarro-Yepes Juliana , Kettner Nicole M. , Rao Xiayu , Bishop Cassandra Santaella , Bui Tuyen N. , Wingate Hannah F. , Singareeka Raghavendra Akshara , Wang Yan , Wang Jing , Sahin Aysegul A. , Meric-Bernstam Funda , Hunt Kelly K. , Damodaran Senthil , Tripathy Debu , Keyomarsi Khandan
Published: October 2023

Abstract
Cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, resistance to CDK4/6is plus ET remains a clinical problem with limited therapeutic options following disease progression. Different CDK4/6is might have distinct mechanisms of resistance, and therefore using them sequentially or targeting their differentially altered pathways could delay disease progression. To understand pathways leading to resistance to the CDK4/6is palbociclib and abemaciclib, we generated multiple in vitro models of palbociclib-resistant (PR) and abemaciclib-resistant (AR) cell lines as well as in vivo patient-derived xenografts (PDX) and ex vivo PDX-derived organoids (PDxO) from patients who progressed on CDK4/6i. PR and AR breast cancer cells exhibited distinct transcriptomic and proteomic profiles that sensitized them to different classes of inhibitors; PR cells upregulated G2–M pathways and responded to abemaciclib, while AR cells upregulated mediators of the oxidative phosphorylation pathway (OXPHOS) and responded to OXPHOS inhibitors. PDX and organoid models derived from patients with PR breast cancer remained responsive to abemaciclib. Resistance to palbociclib while maintaining sensitivity to abemaciclib was associated with pathway-specific transcriptional activity but was not associated with any individual genetic alterations. Finally, data from a cohort of 52 patients indicated that patients with HR-positive/HER2-negative MBC who progressed on palbociclib-containing regimens can exhibit a meaningful overall clinical benefit from abemaciclib-based therapy when administered after palbociclib. These findings provide the rationale for clinical trials evaluating the benefit of abemaciclib treatment following progression on a prior CDK4/6i.
Significance:
Palbociclib-resistant breast cancers respond to abemaciclib and express pathway-specific signatures of sensitivity, providing a biomarker-driven therapeutic option for patients with metastatic breast cancer following disease progression on cyclin-dependent kinases 4/6 inhibitors.
Supplementary Table S2 from Socioeconomic Status at Birth and Breast Tissue Composition in Adolescence and Adulthood
Authors: Kehm Rebecca D. , Lilge Lothar , Walter E. Jane , White Melissa , Herbstman Julie B. , Perera Frederica P. , Miller Rachel L. , Terry Mary Beth , Tehranifar Parisa
Published: October 2023

Supplementary Table S2 shows the characteristics of adolescent girls by maternal education at birth in the Columbia Breast Cancer and the Environment Research Program (Columbia-BCERP) Study, n = 165.
Supplementary Figure S1 from Socioeconomic Status at Birth and Breast Tissue Composition in Adolescence and Adulthood
Authors: Kehm Rebecca D. , Lilge Lothar , Walter E. Jane , White Melissa , Herbstman Julie B. , Perera Frederica P. , Miller Rachel L. , Terry Mary Beth , Tehranifar Parisa
Published: October 2023

Supplementary Figure S1 shows how adolescent girls in the study were classified into the composite socioeconomic status index based on their annual household income and maternal education at birth.
Supplementary Table S3 from Urine pH and Risk of Bladder Cancer in Northern New England
Authors: Fischer Alexander H. , Wong Jason Y.Y. , Baris Dalsu , Koutros Stella , Karagas Margaret R. , Schwenn Molly , Johnson Alison , Alguacil Juan , Silverman Debra T. , Rothman Nathaniel
Published: October 2023

Supplementary Table S3 shows spot urine pH categorized into ≤6.0 and >6.0 and bladder cancer risk, stratified by smoking status.
Supplementary Table S2 from Urine pH and Risk of Bladder Cancer in Northern New England
Authors: Fischer Alexander H. , Wong Jason Y.Y. , Baris Dalsu , Koutros Stella , Karagas Margaret R. , Schwenn Molly , Johnson Alison , Alguacil Juan , Silverman Debra T. , Rothman Nathaniel
Published: October 2023

Supplementary Table S2 shows urine pH and bladder cancer risk stratified by never-, former-, and current-smokers.
Supplementary Table S1 from Urine pH and Risk of Bladder Cancer in Northern New England
Authors: Fischer Alexander H. , Wong Jason Y.Y. , Baris Dalsu , Koutros Stella , Karagas Margaret R. , Schwenn Molly , Johnson Alison , Alguacil Juan , Silverman Debra T. , Rothman Nathaniel
Published: October 2023

Supplementary Table S1 shows urine pH and risk of bladder cancer among ever-smokers.
Supplementary Table S4 from Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: October 2023

Supplementary Table S4: Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (For Pheno Age Acceleration; NMIBC patients without BCG treatment; N = 512)
Supplementary Table S3 from Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: October 2023

Supplementary Table S3: Cox proportional hazards models of immune cell proportions and NMIBC patient outcomes (For Hannum Age Acceleration)
Supplementary Table S1 from Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: October 2023

Supplementary Table S1: Cox proportional hazards multivariable models for age acceleration of 601 NMIBC patients
Supplementary Figure S4 from Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: October 2023

Supplementary Figure S4: Blood immune cell profiles, age and age acceleration distribution of two clusters assigned by the SS-RPMM approach in NMIBC patients
Supplementary Figure S3 from Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: October 2023

Supplementary Figure S3: Semi-Supervised Recursively Partitioned Mixture Model (SS-RPMM) for 10-year overall survival (OS) in NMIBC patients [For Hannum age acceleration]
Supplementary Table S5 from Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin H. , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: October 2023

SNPs in adiponectin and leptin receptor genes and their association with receptor expression
Supplementary Table S3 from Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin H. , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: October 2023

Association between SNPs in the leptin receptor gene and pancreatic cancer mortality by sex
Supplementary Figure S2 from Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin H. , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: October 2023

Association between adiponectin levels and pancreatic cancer mortality using spline regression.
Supplementary Figure S1 from Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin H. , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: October 2023

Association between leptin levels and pancreatic cancer mortality using spline regression.
Table S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Authors: Dalmat Ronit R. , Ziebell Rebecca A. , Kamineni Aruna , Phipps Amanda I. , Weiss Noel S. , Breslau Erica S. , Burnett-Hartman Andrea N. , Corley Douglas A. , Doria-Rose V. Paul , Green Beverly B. , Halm Ethan A. , Levin Theodore R. , Schottinger Joanne E. , Chubak Jessica
Published: October 2023

Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
Supplementary Table 1 from Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study
Authors: Ma Chaoran , Wang Xiaoyu , Dai James Y. , Turman Constance , Kraft Peter , Stopsack Konrad H. , Loda Massimo , Pettersson Andreas , Mucci Lorelei A. , Stanford Janet L. , Penney Kathryn L.
Published: October 2023

Associations of previously reported prostate cancer risk variants with ERG fusion status in the Health Professionals Follow-up Study/Physicians Health Study (HPFS/PHS) and Fred Hutchinson (FH) Prostate Cancer Study.
Figure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Authors: Van Loon Katherine , Mmbaga Elia J. , Mushi Beatrice P. , Selekwa Msiba , Mwanga Ally , Akoko Larry O. , Mwaiselage Julius , Mosha Innocent , Ng Dianna L. , Wu Wei , Silverstein Jordyn , Mulima Gift , Kaimila Bongani , Gopal Satish , Snell Jeff M. , Benz Stephen Charles , Vaske Charles , Sanborn Zack , Sedgewick Andrew J. , Radenbaugh Amie , Newton Yulia , Collisson Eric A.
Published: October 2023

Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
Supplementary Table 1 from Association between Outdoor Light at Night and Prostate Cancer in the Health Professionals Follow-up Study
Authors: Chowdhury-Paulino Ilkania M. , Hart Jaime E. , James Peter , Iyer Hari S. , Wilt Grete E. , Booker Benjamin D. , Nethery Rachel C. , Laden Francine , Mucci Lorelei A. , Markt Sarah C.
Published: October 2023

Supplementary Table 1. Hazard ratios and 95% confidence intervals for the association between cumulative average outdoor light at night (LAN) and lethal prostate cancer risk in HPFS (1986-2016)
Supplementary Figure 1 from Association between Outdoor Light at Night and Prostate Cancer in the Health Professionals Follow-up Study
Authors: Chowdhury-Paulino Ilkania M. , Hart Jaime E. , James Peter , Iyer Hari S. , Wilt Grete E. , Booker Benjamin D. , Nethery Rachel C. , Laden Francine , Mucci Lorelei A. , Markt Sarah C.
Published: October 2023

Supplementary Figure 1. Cubic splines to check for nonlinearity (A) Spline for total prostate cancer; (B) Spline for fatal prostate cancer
Supplementary Table S5 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Table S5. Multivariate MR estimates of direct causal effects of traits on lung cancer dually conditioned on genetically influenced smoking and educational attainment
Supplementary Table S4 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Table S4. Multivariate MR estimates of direct causal effects of traits on lung cancer individually conditioned on genetically influenced smoking, alcohol use, socioeconomic status, and educational attainment.
Supplementary Table S3 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Table S3. Univariate MR estimations of total causal effects between traits with lung cancer risks.
Supplementary Table S2 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Table S2. Complete list of SNPs used as genetic instrumental variables (IVs) for causal effect modeling of traits with lung cancer outcomes.
Supplementary Table S1 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Table S1. Overview of Transdisciplinary Research of Cancer in Lung of the International Lung Cancer Consortium (TRICL-ILCCO) and the OncoArray Consortium GWAS studies
Supplementary Figure S3 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Figure S3. IVW multivariate MR estimation of direct impact of traits on small cell lung cancer development, conditioned on smoking (pack years per lifespan), income, and education.
Supplementary Figure S2 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: October 2023

Supplementary Figure S2. IVW multivariate MR estimation of direct impact of traits on lung squamous cell carcinoma development, conditioned on smoking (pack years per lifespan), income, and education.
Supplementary Table 4 from Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race–Ethnicity: A SEER-Medicare Study
Authors: Herbach Emma L. , Nash Sarah H. , Lizarraga Ingrid M. , Carnahan Ryan M. , Wang Kai , Ogilvie Amy C. , Curran Michaela , Charlton Mary E.
Published: October 2023

Supplementary Table 4 shows a sensitivity analysis: rate ratios for all outcomes adjusted for all covariates except marital status and low-income subsidy.
Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Authors: Cheng En , Caan Bette J. , Cawthon Peggy M. , Evans William J. , Hellerstein Marc K. , Shankaran Mahalakshmi , Nyangau Edna , Campbell Kristin L. , Lee Catherine , Binder Alexandra M. , Meyerhardt Jeffrey A. , Schmitz Kathryn H. , Cespedes Feliciano Elizabeth M.
Published: October 2023

Supplementary Table 6. Sex-Specific Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
Supplementary Table 1 from Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race–Ethnicity: A SEER-Medicare Study
Authors: Herbach Emma L. , Nash Sarah H. , Lizarraga Ingrid M. , Carnahan Ryan M. , Wang Kai , Ogilvie Amy C. , Curran Michaela , Charlton Mary E.
Published: October 2023

Supplementary Table 1 provides detailed definitions for all study variables, including billing codes and data sources used.
Supplementary Figure 1 from Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race–Ethnicity: A SEER-Medicare Study
Authors: Herbach Emma L. , Nash Sarah H. , Lizarraga Ingrid M. , Carnahan Ryan M. , Wang Kai , Ogilvie Amy C. , Curran Michaela , Charlton Mary E.
Published: October 2023

Supplementary Figure 1 describes the process for combining multiple data sources to create a race-ethnicity variable using the best available (and most accurate) data.
Supplemental Table 6 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Table 6: Total number of mutations across 12 cancer predisposing genes among ovarian cancer cases and controls in the NHS, NHSII, and CPSII
Supplemental Table 5 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Table 5: Mutation frequencies in ovarian cancer cases and controls in the NHS, NHSII, and CPSII cohorts separately
Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Authors: Cheng En , Caan Bette J. , Cawthon Peggy M. , Evans William J. , Hellerstein Marc K. , Shankaran Mahalakshmi , Nyangau Edna , Campbell Kristin L. , Lee Catherine , Binder Alexandra M. , Meyerhardt Jeffrey A. , Schmitz Kathryn H. , Cespedes Feliciano Elizabeth M.
Published: October 2023

Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
Supplemental Table 4 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Table 4: Mutation frequencies in high grade serous, endometroid, or poorly differentiated ovarian cancer cases and controls and risk of ovarian cancer in the NHS, NHSII, and CPSII
Supplemental Table 3 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Table 3: Mutation frequencies in invasive ovarian cancer cases and controls and risk of ovarian cancer in the NHS, NHSII, and CPSII
Supplemental Table 1 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Table 1: Characteristics from cohort (2004 NHS; 2007 NHSII, and baseline in CPSII) compared to women with blood or cheek sample
Supplemental Figure 2 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Figure 2: Kaplan-Meier survival curves for ovarian cancer-specific mortality among cases with Type II tumors (high/unknown grade serous, poorly differentiated, or high grade endometrioid) for A) BRCA1 mutation carriers, B) BRCA2 mutation carriers (solid black lines). Grey lines are women with no mutation in any of the measured high-penetrance genes. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox Proportional hazard models and were adjusted for age at diagnosis (continuous), year of ovarian cancer diagnosis (continuous), and stage (0, I, II, III, IV, Unknown)
Supplemental Figure 1 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts
Authors: Kotsopoulos Joanne , Hathaway Cassandra A. , Narod Steven A. , Teras Lauren R. , Patel Alpa V. , Hu Chunling , Yadav Siddhartha , Couch Fergus J. , Tworoger Shelley S.
Published: October 2023

Supplemental Figure 1: Kaplan-Meier survival curves for all-cause mortality among cases with Type II tumors (high/unknown grade serous, poorly differentiated, or high grade endometrioid) for A) BRCA1 mutation carriers, B) BRCA2 mutation carriers (solid black lines). Grey lines are women with no mutation in any of the measured high-penetrance genes. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox Proportional hazard models and were adjusted for age at diagnosis (continuous), year of ovarian cancer diagnosis (continuous), and stage (0, I, II, III, IV, Unknown)
Table S2 from Associations between Ambient Air Pollutants and Clonal Hematopoiesis of Indeterminate Potential
Authors: Leiser Claire L. , Whitsel Eric A. , Reiner Alexander , Rich Stephen S. , Rotter Jerome I. , Taylor Kent D. , Tracy Russel P. , Kooperberg Charles , Smith Albert Vernon , Manson JoAnn E. , Mychaleckyj Josyf C. , Bick Alexander G. , Szpiro Adam A. , Kaufman Joel D.
Published: October 2023

Supplementary Table 2 shows additional results for non smokers and never smokers in the MESA and WHI cohorts.
Table S1 from Associations between Ambient Air Pollutants and Clonal Hematopoiesis of Indeterminate Potential
Authors: Leiser Claire L. , Whitsel Eric A. , Reiner Alexander , Rich Stephen S. , Rotter Jerome I. , Taylor Kent D. , Tracy Russel P. , Kooperberg Charles , Smith Albert Vernon , Manson JoAnn E. , Mychaleckyj Josyf C. , Bick Alexander G. , Szpiro Adam A. , Kaufman Joel D.
Published: October 2023

Supplementary table1 shows additional results for correction for sampling in the WHI cohort
Figure S1 from Associations between Ambient Air Pollutants and Clonal Hematopoiesis of Indeterminate Potential
Authors: Leiser Claire L. , Whitsel Eric A. , Reiner Alexander , Rich Stephen S. , Rotter Jerome I. , Taylor Kent D. , Tracy Russel P. , Kooperberg Charles , Smith Albert Vernon , Manson JoAnn E. , Mychaleckyj Josyf C. , Bick Alexander G. , Szpiro Adam A. , Kaufman Joel D.
Published: October 2023

Figure S1 shows the sample selection for the WHI and MESA cohorts in TOPMed.